Assisted reproductive technology outcomes in childhood cancer survivors: A report from the Childhood Cancer Survivor Study.

Authors

null

Kimberly W. Keefe

Brigham and Women's Hospital, Boston, MA

Kimberly W. Keefe , Andrea Lanes , Kayla Stratton , Daniel M. Green , Eric Jessen Chow , Kevin C. Oeffinger , Sara Barton , Lisa Diller , Yutaka Yasui , Wendy M. Leisenring , Gregory T. Armstrong , Elizabeth S. Ginsburg

Organizations

Brigham and Women's Hospital, Boston, MA, Fred Hutchinson Cancer Research Center, Seattle, WA, St. Jude Children's Research Hospital, Memphis, TN, Duke University, Durham, NC, Colorodo Center for Reproductive Medicine, Denver, CO, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

Research Funding

U.S. National Institutes of Health
U.S. National Institutes of Health, Institutional funding from Brigham and Women's Hospital (Expanding the Boundaries Grant)

Background: Some treatment exposures for childhood cancer reduce ovarian reserve. Registry-based evaluation has not been conducted for assisted reproductive technology (ART) outcomes of female survivors. Methods: The Childhood Cancer Survivor Study, a retrospective cohort of five-year survivors and siblings, was linked to the Society for Assisted Reproductive Technology Clinic Outcome Reporting System (SART CORS), which captures nationwide, CDC-required reporting of ART outcomes. We assessed live birth rate and relative risk (RR, 95% CI) as a function of treatment exposure, using generalized estimating equation to account for multiple ovarian stimulations per subject. Results: Among 9885 female survivors, 137 (1.4%; median age at diagnosis 10 years, range 0-20; 11 years of follow-up, 2-11) underwent 243 ART cycles (mean 1.8 cycles) and among 2419 siblings, 33 (1.4%) underwent 60 ART cycles (mean 1.8). Median age at autologous egg retrieval was 30 years (19-44) for survivors and 34 (24-43) for siblings. In the subset using autologous eggs (Table), 99 survivors underwent 155 ovarian stimulation cycles that resulted in 113 embryo transfers and 49 live births for a live birth rate of 32% per ovarian stimulation and 43% per transfer. Sibling live birth rate was 38% (p = 0.39 compared to survivors) per autologous ovarian stimulation and 53% (p = 0.33) per transfer. 38 survivors and 1 sibling underwent egg donor ovarian stimulation cycles. Two survivors used autologous eggs with gestational carriers and one cycle resulted in live birth. Cranial radiation therapy (RT) [RR 0.48 (0.27-0.87) p = 0.02] and pelvic RT [0.30 (0.14-0.66) p = 0.002], compared with no RT, resulted in lower RR of live birth in survivors. The likelihood of live birth after ART in survivors was not impacted by alkylator exposure [CED < 8000 mg/m2 vs. none: 1.14 (0.65-2.02); CED >8000 mg/m2 vs none: 1.07 (0.06-1.91)]. Conclusions: While live birth rates among survivors were lower compared with siblings, differences were not statistically significant. Pelvic and cranial RT were associated with a decreased likelihood of live birth, with no association with alkylator exposure identified.

DiagnosisOvarian stimulations (N = 155)Embryo transfer (N = 113)Live birth per ovarian stimulation (N = 49)
Neuroblastoma14149(64%)
Bone cancer15107(47%)
Soft tissue sarcoma954(44%)
CNS1285(42%)
Kidney (Wilms)16105(31%)
NHL1063(30%)
Leukemia40299(23%)
HD39317(18%)

U.S. National Institutes of Health Institutional funding from Brigham and Women's Hospital (Expanding the Boundaries Grant)

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Discussion Session

Session Title

Pediatric Oncology

Track

Pediatric Oncology

Sub Track

Survivorship

Citation

J Clin Oncol 38: 2020 (suppl; abstr 10528)

DOI

10.1200/JCO.2020.38.15_suppl.10528

Abstract #

10528

Poster Bd #

415

Abstract Disclosures